Today’s Research Reports on Stocks to Watch: Ultragenyx Pharmaceutical and CRISPR Therapeutics

NEW YORK, NY / ACCESSWIRE / February 27, 2018 / Ultragenyx and CRISPR Therapeutics both closed high in the green on Monday. Ultragenyx recently had positive news regarding Crysvita, an anti-FGF23 fully human monoclonal antibody which is now the first treatment to target the underlying pathophysiology of XLH disorder. CRISPR soared to a new high despite any significant catalyst.

RDI Initiates Coverage on:

Ultragenyx Pharmaceutical Inc.

https://rdinvesting.com/news/?ticker=RARE

CRISPR Therapeutics AG
https://rdinvesting.com/news/?ticker=CRSP

Ultragenyx Pharmaceutical’s shares closed up 4.33% on Monday with about 412,000 shares traded. There was no particular news from the company yesterday but last week it was announced by company as well as Kyowa Hakko Kirin Co. Ltd, and Kyowa Kirin International PLC, that Crysvita has received a positive European Commission decision that grants conditional marketing authorization to Kyowa Kirin for the treatment of X-linked hypophosphatemia (XLH) with radiographic evidence of bone disease in children 1 year of age and older and adolescents with growing skeletons. Crysvita is the very first treatment for XLH that targets the underlying cause and pathophysiology of the disease. XLH is a rare and chronic progressive musculoskeletal disorder. CEO of Kyowa Kirin International, Dr. Tom Stratford commented, “Today’s news brings hope to people affected by XLH in Europe, and it’s exciting that Europe is the first global regulatory approval for Crysvita. We will now focus our efforts on working with health authorities to ensure patient access in European countries.” Ultragenyx CEO Emil D. Kakkis M.D., Ph.D., stated, “XLH is extremely debilitating to patients and this authorisation in Europe provides children with the first treatment option that addresses the excess FGF23 activity in XLH,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. “Through this authorization and our work throughout the rest of the world we are committed to bringing Crysvita to all patients with XLH who could benefit from the therapy.”

Access RDI’s Ultragenyx Pharmaceutical Inc. Research Report at:
https://rdinvesting.com/news/?ticker=RARE

CRISPR Therapeutics’ shares were on fire in Monday trading and closed the day up 12.31%. The stock soared to a new high of $49.72 during intra-day trading on trading volume more than double compared to usual. There was no significant news from the company but it was revealed in a recent 13F filing with the SEC, that Artal Group S.A. has bought a position in the company. The fund has purchased 50,000 shares of the stock valued at $1,174,000. It was announced last week that the genome editing company will have members of its senior management team attend four upcoming investor conferences. One was last week, the RBC Capital Markets Global Healthcare Conference on February 22nd. The others are the Barclays Global Healthcare Conference on March 13th, the Guggenheim Conference on Disruptive Technologies in Immuno-Oncology on March 27th, and the 17th Annual Needham Healthcare Conference on March 28th.

Access RDI’s CRISPR Therapeutics AG Research Report at:
https://rdinvesting.com/news/?ticker=CRSP

Our Actionable Research on Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and CRISPR Therapeutics AG (NASDAQ: CRSP) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 490863